JP2022538609A - 新規な癌抗原及び方法 - Google Patents

新規な癌抗原及び方法 Download PDF

Info

Publication number
JP2022538609A
JP2022538609A JP2021577385A JP2021577385A JP2022538609A JP 2022538609 A JP2022538609 A JP 2022538609A JP 2021577385 A JP2021577385 A JP 2021577385A JP 2021577385 A JP2021577385 A JP 2021577385A JP 2022538609 A JP2022538609 A JP 2022538609A
Authority
JP
Japan
Prior art keywords
cancer
polypeptide
cells
antigen
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577385A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020260898A5 (https=
JP2022538609A5 (https=
Inventor
カシオティス ジョージ
ヤング ジョージ
アッティグ ジャン
マリノ ファビオ
Original Assignee
ザ フランシス クリック インスティチュート リミティッド
エナラ バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ フランシス クリック インスティチュート リミティッド, エナラ バイオ リミテッド filed Critical ザ フランシス クリック インスティチュート リミティッド
Publication of JP2022538609A publication Critical patent/JP2022538609A/ja
Publication of JPWO2020260898A5 publication Critical patent/JPWO2020260898A5/ja
Publication of JP2022538609A5 publication Critical patent/JP2022538609A5/ja
Priority to JP2024197303A priority Critical patent/JP2025032114A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
JP2021577385A 2019-06-28 2020-06-26 新規な癌抗原及び方法 Pending JP2022538609A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197303A JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183396 2019-06-28
EP19183396.1 2019-06-28
PCT/GB2020/051558 WO2020260898A2 (en) 2019-06-28 2020-06-26 Novel cancer antigens and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197303A Division JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Publications (3)

Publication Number Publication Date
JP2022538609A true JP2022538609A (ja) 2022-09-05
JPWO2020260898A5 JPWO2020260898A5 (https=) 2023-07-18
JP2022538609A5 JP2022538609A5 (https=) 2023-07-18

Family

ID=67145533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577385A Pending JP2022538609A (ja) 2019-06-28 2020-06-26 新規な癌抗原及び方法
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220218807A1 (https=)
EP (1) EP3990007A2 (https=)
JP (2) JP2022538609A (https=)
KR (1) KR20220029560A (https=)
CN (2) CN119119228A (https=)
AU (1) AU2020307943A1 (https=)
BR (1) BR112021026375A2 (https=)
CA (1) CA3141229A1 (https=)
IL (1) IL289205A (https=)
MX (1) MX2021015766A (https=)
WO (1) WO2020260898A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途
WO2022229647A1 (en) 2021-04-28 2022-11-03 Enara Bio Limited Novel cancer antigens and methods
WO2025133007A1 (en) 2023-12-19 2025-06-26 Enara Bio Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025224446A1 (en) 2024-04-23 2025-10-30 Enara Bio Limited Novel cancer antigens and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004385A2 (en) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US20140099324A1 (en) * 2006-05-22 2014-04-10 Board Of Regents, The University Of Texas System Herv-k antigens, antibodies, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US6488931B1 (en) * 1998-12-17 2002-12-03 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP3563835A4 (en) * 2016-12-29 2020-12-30 Korea Institute of Science and Technology NEW EXOSOME-BASED ANTI-CANCER AGENT
KR101964124B1 (ko) * 2017-03-28 2019-04-01 한국과학기술연구원 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도
KR101869518B1 (ko) * 2018-03-28 2018-06-20 황인후 췌장암 줄기세포의 emt-met 가소성을 이용한 암 치료용 수지상 세포 백신의 제조 방법
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140099324A1 (en) * 2006-05-22 2014-04-10 Board Of Regents, The University Of Texas System Herv-k antigens, antibodies, and methods
WO2014004385A2 (en) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines

Also Published As

Publication number Publication date
MX2021015766A (es) 2022-01-27
WO2020260898A2 (en) 2020-12-30
EP3990007A2 (en) 2022-05-04
KR20220029560A (ko) 2022-03-08
WO2020260898A3 (en) 2021-02-04
IL289205A (en) 2022-02-01
US20220218807A1 (en) 2022-07-14
CA3141229A1 (en) 2020-12-30
BR112021026375A2 (pt) 2022-05-10
JP2025032114A (ja) 2025-03-11
CN119119228A (zh) 2024-12-13
AU2020307943A1 (en) 2021-12-02
CN114341168A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
JP2022538609A (ja) 新規な癌抗原及び方法
US12263216B2 (en) Cancer antigens and methods
US20220213159A1 (en) Novel cancer antigens and methods
US20220220175A1 (en) Novel cancer antigens and methods
US20220211760A1 (en) Novel cancer antigens and methods
US20240156932A1 (en) Novel cancer antigens and methods
EA052615B1 (ru) Новые раковые антигены и сопутствующие способы
EA052067B1 (ru) Новые раковые антигены и сопутствующие способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203